{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma%2C+Pancreatic+Ductal&page=14", "query": { "condition": "Adenocarcinoma, Pancreatic Ductal", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 404, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma%2C+Pancreatic+Ductal&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma%2C+Pancreatic+Ductal&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T04:20:19.406Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03970252", "title": "Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Borderline Resectable Pancreatic Adenocarcinoma", "Resectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-07-24", "completion_date": "2024-05-25", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03970252" }, { "nct_id": "NCT01839487", "title": "PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "PEGPH20", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 279, "start_date": "2013-05-14", "completion_date": "2018-09-26", "has_results": true, "last_update_posted_date": "2020-07-20", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01839487" }, { "nct_id": "NCT06077487", "title": "Ketamine-assisted Therapy for Advanced GI Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Pain, Acute", "Gastrointestinal Cancers", "Demoralization" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Ketamine Injectable Product", "type": "DRUG" }, { "name": "Meaning and Purpose therapy", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Questionnaires", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "OTHER" ], "sponsor": "Brian Anderson, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-05-17", "completion_date": "2025-01-31", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06077487" }, { "nct_id": "NCT00004604", "title": "Biological Therapy in Treating Patients With Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Lung Cancer", "Metastatic Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "CEA RNA-pulsed DC cancer vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "1997-02", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2013-02-22", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004604" }, { "nct_id": "NCT04853017", "title": "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Minimal Residual Disease", "KRAS G12D", "KRAS G12R", "NRAS G12D", "NRAS G12R", "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "Non-small Cell Lung Cancer", "Ovarian Cancer", "Cholangiocarcinoma", "Bile Duct Cancer", "Gallbladder Carcinoma" ], "interventions": [ { "name": "ELI-002 2P", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elicio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-10-04", "completion_date": "2024-09-24", "has_results": true, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04853017" }, { "nct_id": "NCT05132504", "title": "Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Folfirinox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-08-31", "completion_date": "2027-05-21", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 3, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05132504" }, { "nct_id": "NCT06287463", "title": "Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "RAF Mutation", "RAS Mutation", "NF1 Mutation", "Non-Small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Melanoma", "BRAF Gene Mutation", "CRAF Gene Mutation", "Castration-Resistant Prostate Cancer (CRPC)" ], "interventions": [ { "name": "DCC-3084", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2024-05-14", "completion_date": "2026-02-13", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06287463" }, { "nct_id": "NCT01155258", "title": "Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer", "Hereditary Paraganglioma", "Male Breast Cancer", "Malignant Paraganglioma", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Pheochromocytoma", "Pancreatic Polypeptide Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Neuroendocrine Carcinoma of the Skin", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pheochromocytoma", "Recurrent Prostate Cancer", "Recurrent Renal Cell Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Uterine Sarcoma", "Regional Gastrointestinal Carcinoid Tumor", "Regional Pheochromocytoma", "Stage III Cervical Cancer", "Stage III Endometrial Carcinoma", "Stage III Neuroendocrine Carcinoma of the Skin", "Stage III Ovarian Epithelial Cancer", "Stage III Ovarian Germ Cell Tumor", "Stage III Prostate Cancer", "Stage III Renal Cell Cancer", "Stage III Uterine Sarcoma", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Neuroendocrine Carcinoma of the Skin", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IV Uterine Sarcoma", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2010-06", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01155258" }, { "nct_id": "NCT04990609", "title": "EUS-RFA PANCARDINAL-1 Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)", "type": "DEVICE" }, { "name": "Neoadjuvant Chemotherapy (NAC)", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-08-13", "completion_date": "2028-05-30", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990609" }, { "nct_id": "NCT07089940", "title": "OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Locally Advanced Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Myc Inhibitor OMO-103", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2026-01-27", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-14T04:20:19.406Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07089940" } ] }